Tumor News and Research

RSS

Combination of hormones may effectively treat obesity with few side effects

Scientists at Indiana University and international collaborators have found a way to link two hormones into a single molecule, producing a more effective therapy with fewer side effects for potential use as treatment for obesity and related medical conditions.

14 Nov 2012

FDA accepts Navidea’s resubmitted NDA for Lymphoseek

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.

14 Nov 2012

Tiltan Pharma initiates enrollment in TL-118 Phase 2 trial for metastatic pancreatic cancer

Tiltan Pharma Ltd. today announced that it has enrolled the first U.S. patient, at White Plains Hospital in Westchester County N.Y., in a Phase 2 clinical trial of its anti-angiogenic product, TL-118, for the treatment of metastatic pancreatic cancer.

14 Nov 2012

IDMC reviews data from Nanobiotix’s NBTXR3 Phase I study on advanced soft tissue sarcoma

Nanobiotix, announced today that the Independent Data Monitoring Committee (IDMC) has reviewed the data of the first 6 patients treated in the phase I Study with the lead product NBTXR3 for the treatment of advanced Soft Tissue Sarcoma of the extremity. Based on the review of the safety data, the IDMC has unanimously recommended continuing the enrollment in the study according to the protocol. This trial is realized in the Institut Gustave Roussy, France.

13 Nov 2012

Cancer metastasis research facilitated by nanoparticle characterization technology from NanoSight

NanoSight, leading manufacturers of unique nanoparticle characterization technology, reports on the breakthrough cancer metastasis research of Dr. Hector Peinado Selgas and Dr. David Lyden's research team from Weill Cornell Medical College.

13 Nov 2012

White kidney cancer patients have a survival advantage over blacks

Among patients with the most common form of kidney cancer, whites consistently have a survival advantage over blacks, regardless of patient and tumor characteristics or surgical treatment.

12 Nov 2012

Mastoscopic axillary lymph node dissection can reduce breast cancer complications

Axillary lymph node dissection is done in conjunction with lumpectomy or mastectomy to determine if breast cancer has spread to the adjoining lymph nodes. The conventional surgical approach leaves a surgical scar that is unattractive and can restrict range of motion in the shoulder joint. Also, squeezing and pulling the tumor during the breast operation can stimulate tumor cell metastases.

9 Nov 2012

Glycemic load raises colon cancer recurrence risk

Increased glycemic loads and high carbohydrate consumption may increase the risk for colon cancer recurrence, show the results of a US study.

8 Nov 2012

Oral verrucous lesions need special diagnostic attention

Care should be taken to diagnose oral verrucous lesions accurately according to their nature, behavior, and malignant potential, and should be differentiated from grade I squamous cell carcinoma, suggest Indian researchers.

8 Nov 2012

Ocular sebaceous carcinoma rare, but often misdiagnosed in UK

Ocular sebaceous carcinoma is rare in the UK, say researchers in the British Journal of Ophthalmology.

8 Nov 2012

Pevion launches Defensomes platform for broad spectrum immune enhancement

Pevion Biotech AG today announced the launch of a new program called Defensomes, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 million doses applied to humans to date. Defensomes offer opportunities for a wide range of prophylactic and therapeutic indications, where boosting of the body's own natural defense is beneficial.

8 Nov 2012

Patient recruitment complete for immatics IMA901 Phase 3 trial for renal cell carcinoma

immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, announced today that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma (RCC). The trial has completed patient inclusion and it is expected that around 345 patients will be randomized across 10 countries in the US and Europe.

8 Nov 2012

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

Aileron Therapeutics, Inc. and its collaborator Roche today announced new results of a preclinical study of its Stapled Peptide oncology drug candidate ATSP-7041, which exhibited robust efficacy in MDM2 and MDMX xenograft cancer models.

8 Nov 2012

Thyroid journal publishes new ATA guidelines for management of anaplastic thyroid cancer

Anaplastic thyroid cancer is a rare form of thyroid tumor, but it is also the most deadly. Newly developed evidence-based recommendations for the diagnosis, treatment, and long-term monitoring and follow-up care of patients with this extremely aggressive form of thyroid cancer are published in Thyroid, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

8 Nov 2012

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention.

7 Nov 2012

Ion AmpliSeq Community Panels from Life Technologies

Life Technologies Corporation today announced Ion AmpliSeq Community Panels, a community-driven solution to gene panel sequencing that leverages the expertise of scientific thought leaders and the Ion Community to create gene panels for conditions ranging from cancer to inherited diseases.

7 Nov 2012

Cloud technology helps researchers collect detailed information from cancer cell samples

Storing music and photos on distant computers via "cloud" technology is nothing new. But Johns Hopkins researchers are now using this tactic to collect detailed information from thousands of cancer cell samples. The goal is to help doctors make better predictions about how a patient's illness will progress and what type of treatment will be most effective.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Several substances inhibiting so-called HDAC enzymes have been studied in trials searching for new anti-cancer drugs in recent years. "Trials have shown that HDAC inhibitors are very effective in arresting growth of cultured cancer cells. But apart from a very rare type of lymphoma, these drugs unfortunately do not clinically affect malignant tumors," says Prof. Dr. Olaf Witt, who heads a research department at DKFZ and is pediatrician at the Center for Child and Adolescent Medicine of Heidelberg University Hospital.

6 Nov 2012

Peptide-enhanced tomatoes reduce atherosclerosis in mice

For the first time, genetically engineered tomato plants produced a peptide that mimics the actions of good cholesterol when eaten, researchers reported at the American Heart Association's Scientific Sessions 2012.

6 Nov 2012

Tumor News and Research

Combination of hormones may effectively treat obesity with few side effects

FDA accepts Navidea’s resubmitted NDA for Lymphoseek

Tiltan Pharma initiates enrollment in TL-118 Phase 2 trial for metastatic pancreatic cancer

IDMC reviews data from Nanobiotix’s NBTXR3 Phase I study on advanced soft tissue sarcoma

Cancer metastasis research facilitated by nanoparticle characterization technology from NanoSight

White kidney cancer patients have a survival advantage over blacks

Mastoscopic axillary lymph node dissection can reduce breast cancer complications

Glycemic load raises colon cancer recurrence risk

Oral verrucous lesions need special diagnostic attention

Ocular sebaceous carcinoma rare, but often misdiagnosed in UK

Pevion launches Defensomes platform for broad spectrum immune enhancement

Patient recruitment complete for immatics IMA901 Phase 3 trial for renal cell carcinoma

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

Thyroid journal publishes new ATA guidelines for management of anaplastic thyroid cancer

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

Ion AmpliSeq Community Panels from Life Technologies

Cloud technology helps researchers collect detailed information from cancer cell samples

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Peptide-enhanced tomatoes reduce atherosclerosis in mice

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News